US RE50,455 E1
Pyrazolopyridine derivative having GLP-1 receptor agonist effect
Hitoshi Yoshino, Shizuoka (JP); Satoshi Tsuchiya, Shizuoka (JP); Atsushi Matsuo, Shizuoka (JP); Tsutomu Sato, Shizuoka (JP); Masahiro Nishimoto, Shizuoka (JP); Kyoko Oguri, Shizuoka (JP); Hiroko Ogawa, Shizuoka (JP); Yoshikazu Nishimura, Shizuoka (JP); Yoshiyuki Furuta, Kanagawa (JP); Hirotaka Kashiwagi, Shizuoka (JP); Nobuyuki Hori, Shizuoka (JP); Takuma Kamon, Shizuoka (JP); Takuya Shiraishi, Shizuoka (JP); Shoshin Yoshida, Shizuoka (JP); Takahiro Kawai, Shizuoka (JP); Satoshi Tanida, Shizuoka (JP); and Masahide Aoki, Shizuoka (JP)
Assigned to CHUGAI SEIYAKU KABUSHIKI KAISHA, Tokyo (JP)
Appl. No. 18/077,060
Filed by Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP)
PCT Filed Sep. 26, 2017, PCT No. PCT/JP2017/034620
§ 371(c)(1), (2) Date Mar. 14, 2018,
PCT Pub. No. WO2018/056453, PCT Pub. Date Mar. 29, 2018.
Application 18/077,060 is a reissue of application No. 15/759,872, filed on Sep. 26, 2017, granted, now 10,858,356, issued on Dec. 8, 2020.
Claims priority of application No. 2016-187605 (JP), filed on Sep. 26, 2016.
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/437 (2006.01); A61K 31/444 (2006.01); A61K 31/4709 (2006.01); A61K 31/4725 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/5386 (2006.01); A61P 1/16 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); A61P 9/10 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); C07D 519/00 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/437 (2013.01); A61K 31/444 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/5386 (2013.01); A61P 1/16 (2018.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A61P 9/10 (2018.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01); C07D 519/00 (2013.01)] 41 Claims
 
[ 18. A compound selected from:

OG Complex Work Unit Chemistry
or a mixture thereof, or a salt thereof.]
 
[ 26. A method for treating hyperglycemia in a patient in need thereof, comprising administering an effective amount of the compound according to claim 18.]